𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutations of the BRAF gene in human cancer

✍ Scribed by Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William


Book ID
109890266
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
349 KB
Volume
417
Category
Article
ISSN
0028-0836

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


BRAF and KRAS mutations in stomach cance
✍ Lee, Sug Hyung; Lee, Jong Woo; Soung, Young Hwa; Kim, Hong Sug; Park, Won Sang; πŸ“‚ Article πŸ“… 2003 πŸ› Nature Publishing Group 🌐 English βš– 141 KB
Mutations of the BRAF gene in ulcerative
✍ Daniela E. Aust; Michael Haase; Lyudmyla Dobryden; Annett Markwarth; Udo LΓΆhrs; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 263 KB πŸ‘ 1 views

## Abstract The __Raf/MEK/ERK (MAPK)__ signal transduction cascade is an important mediator of a number of cellular fates including growth, proliferation and survival. The __BRAF__ gene is activated by oncogenic __Ras__, leading to cooperative effects in cells responding to growth factor signals. O

TRAIL receptor upregulation and the impl
✍ Eftychia Oikonomou; Vivian Kosmidou; Anastasia Katseli; Konstantinos Kothonidis; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 273 KB πŸ‘ 2 views

## Abstract TRAIL raises hopes as a promising anti‐tumor agent due to its selectivity toward cancer cells. Higher expression of its pro‐death receptors TRAIL‐R1 (DR4) and TRAIL‐R2 (DR5) attenuates higher sensitivity to TRAIL‐induced apoptosis, and represents a marker for better cancer prognosis and

Mutation analysis of p53, K-ras, and BRA
✍ Daniele Calistri; Claudia Rengucci; Ian Seymour; Arturo Lattuneddu; Anna maria P πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract Gene mutations in __APC__, __K‐ras__, and __p53__ are thought to be essential events for colorectal cancer development. Recent data seem to indicate that __K‐ras__ and __p53__ mutations rarely co‐exist in the same tumor, indicating that these alterations do not represent a synergistic e